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Abstract: Parkinson’s disease (PD) is recognized as the second most common neurodegenerative
disorder and is characterized by a slow and progressive degeneration of dopaminergic neurons
in the substantia nigra. Despite intensive research, the mechanisms involved in neuronal loss are
not completely understood yet; however, misfolded proteins, oxidative stress, excitotoxicity and
inflammation play a pivotal role in the progression of the pathology. Neuroinflammation may
have a greater function in PD pathogenesis than initially believed, taking part in the cascade of
events that leads to neuronal death. To date, no efficient therapy, able to arrest or slow down
PD, is available. In this context, the need to find novel strategies to counteract neurodegenerative
progression by influencing diseases’ pathogenesis is becoming increasingly clear. Isothiocyanates
(ITCs) have already shown interesting properties in detoxification, inflammation, apoptosis and cell
cycle regulation through the induction of phase I and phase II enzyme systems. Moreover, ITCs may
be able to modulate several key points in oxidative and inflammatory evolution. In view of these
considerations, the aim of the present review is to describe ITCs as pleiotropic compounds capable of
preventing and modulating the evolution of PD.
Keywords: Parkinson’s disease; neuroinflammation; isothiocyanates; neuroprotection; oxidative
stress; NrF2 pathway
1. Introduction
Neurodegenerative diseases are estimated to surpass cancer as the most important cause of death
by the 2040s [1]. Neurons are the bricks that constitute the central nervous system (CNS), and they are
characterized by the inability to reproduce or replace themselves. In this way, when damage threatens,
the loss of cells will be irreversible. The term neurodegeneration defines a variety of conditions that
modify normal neuronal functions in the human brain, where it is possible to observe a progressive
and consistent cells loss. This definition identifies different pathologies, such as Alzheimer’s disease
(AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS), and so
forth. The mechanisms involved in the evolution of these conditions are not completely understood yet;
however, they share common characteristics, such as misfolded proteins, oxidative stress, inflammation,
excitotoxicity and, obviously, neuronal loss [2,3]. These processes can occur both in sporadic and
familial cases, which highlights how these pathological mechanisms are strongly correlated with
neuron dysfunctions [4]. Patients are usually affected later in life; for this reason, in the last 20 years,
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the number of diagnoses is prominently enhanced, especially for the increase in life expectancy.
However, numerous evidences suggest the presence of a preclinical asymptomatic stage that could
begin years before the establishment of the first symptoms. This pre-symptomatic stage could be
considered the key phase, because it represents the time point where it is possible to modulate the
development of the disease [5]. Unfortunately, the current therapy is only symptomatic, and it could
not arrest the progression of the neurodegenerative process [6].
Inflammatory processes have been implicated in neurodegenerative conditions [7]. Inflammation
is a double-faced mechanism: on the one hand, secretory factors, such as cytokines and chemokines,
cause an increased cerebral blood flow to the affected area and the removal of damaged tissue by
phagocytic cells; on the other hand, they increase the production of reactive oxygen species (ROS) and
lead to the destruction of the blood brain barrier (BBB) [8].
Isothiocyanates (ITCs) from cruciferous vegetables have already shown interesting properties
in the induction of phase I and II enzymes involved in detoxification processes, and they have
demonstrated the ability to interfere in the cell cycle regulation promoting the apoptotic pathway [9,10].
Furthermore ITCs are able to modulate the oxidative condition and the inflammatory process [11,12].
These compounds have been widely studied as antitumoral agents [13], and they have also shown
interesting effects against cardiovascular [14–16], CNS [17,18] and skin diseases [19].
In light of these considerations, the aim of the present review is to describe ITCs as potential
neuroprotective compounds in the prevention of PD. In particular, we have summarized the effects
of sulforaphane (SFN), erucin (ER), phenethyl isothiocyanate (PEITC) and 6-(methylsulfinyl)hexyl
isothiocyanate (6-MSITC) on the evolution of PD.
2. Parkinson’s Disease
In 1817, James Parkinson described, in his monography “Essay in the Shaking Palsy”,
the essence of the second most common age-related neurodegenerative disorder after AD [2]. PD is
a neurodegenerative multisystem disorder afflicting approximately six million people worldwide
and characterized by a combination of motor and non-motor symptoms. The main pathological
modifications in the parkinsonian brain are the degeneration of dopaminergic neurons of the substantia
nigra pars compacta (SNpc) in the ventral midbrain and the depletion of dopamine (DA) in the striatum
(STR). SNpc and STR are part of a complex neuronal system that includes cortex, basal ganglia
and thalamus, and it is responsible for the normal motor functions. While the neurons of this
region are preferentially lost in PD, they are not the only ones involved in the progression of the
disease. In addition to neuronal loss, the condition is associated with an accumulation of cytoplasmic,
eosinophilic neuronal inclusions, known as Lewy bodies (LBs), predominantly composed of the
presynaptic protein α-synuclein (α-syn) [2,20]. The exact biological function of this protein and the
mechanism by which it leads to neuronal loss are still not clear, although it has been observed that
an excess of α-syn depositions can cause dopaminergic neuronal death [21].
PD is characterized by cardinal motor symptoms, including bradykinesia, rigidity, postural
instability and resting tremor. During early stages of PD, patients also exhibit non-motor manifestations,
such as autonomic dysfunctions, cognitive abnormalities, sleep and mood disorders, pain and sensory
conditions reflecting the peripheral neurodegeneration [22]. Despite the increasing evidence of their
importance on the quality of life, studies have shown that there are several difficulties in the treatment
of these issues [23].
The current therapy for PD is the administration of 3,4-dihydroxyphenylalanine (L-DOPA),
a precursor of DA. The pathology evolution determines that dopaminergic neurons are continuously
diminished, and the treatment loses efficacy also because it cannot find its own target. Anyway,
the therapy is only palliative and symptomatic, as it cannot arrest the progression of the disease,
but it can only supply the lack of DA [24]. However, there are many symptoms that do not respond
to the dopaminergic therapy. Moreover, the transformation of L-DOPA to DA may contribute to
the increment of ROS and consequently to the progression of the neurodegenerative process.
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Mechanisms Involved in Parkinson’s Disease
Oxidative stress is defined by the imbalance between the levels of ROS produced and
the capacity of biological systems to eliminate or to quench the reactive intermediates formed.
Within evolution, all biological systems have developed adaptive responses that include defensive
enzymes, molecular chaperones and antioxidant molecules [25]. Several pathway are responsible
for ROS formation, such as indirect pathways involving the activation of enzymes, like nitric oxide
synthase (NOS) or nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, or by direct
interactions between oxygen species and redox active metals [26]. The brain is the organ that consumes
the largest percentage of oxygen introduced into the body, with an amount close to the 20%. From the
moment that a significant portion of that oxygen is converted into ROS, this extensive production
could provide an explanation for the crucial role of ROS in PD onset and evolution. On the other hand,
the CNS is characterized by low levels of glutathione (GSH), the most important endogen antioxidant
system, and by high levels of iron and calcium in the SNpc. This condition is essential to establish the
redox imbalance [27,28]. Additionally, polyunsaturated fatty acids are present in high concentrations
in the brain, resulting in the generation of toxic products and lipid peroxidation.
Another important mechanism involved in the pathogenesis of PD is excitotoxicity, which plays
a pathological role that critically contributes to the exacerbation of nigrostriatal degeneration [29].
In PD, the altered neurotransmission observed within the basal ganglia affects the glutamatergic
system, suggesting a critical involvement of glutamate-mediated excitotoxicity in the pathogenesis.
Accumulation of extracellular glutamate and increased stimulation of glutamatergic neurons spreads
ROS production. The activation of glutamate receptors involves calcium homeostasis dysfunction,
caspases activation and determines an increase in cytotoxic transcription factors and free radical
species [30].
Apoptosis is considered as the dominant mechanism of cell death in PD [31]. This process
is characterized by morphological and biochemical alterations involving nuclear chromatin,
cytoplasmatic organelles and endoplasmic reticulum [32]. The apoptotic process is characterized by
two main pathways, extrinsic and intrinsic, that are constituted by a different set of initiator caspases,
but they have the same executioners. Autophagy is another cell death mechanism involved in PD.
Chaperone-mediated autophagy (CMA), which degrades only soluble forms of protein, is responsible
for the α-syn recycle. A percentage of intracellular α-syn modifies the CMA pathway. Instead of
entering for degradation, they accumulate in the cytoplasm, causing cell death [4]. On the other hand,
necrotic cell death does not play a crucial role in a slowly progressive neurodegenerative disorder,
such as PD. Interestingly, in many PD animal models, necrosis is induced by toxins when given in
high doses or for long treatments. Thus, it is possible to underlie how the experimental conditions are
determinant to produce apoptosis or necrosis [33].
3. Neuroinflammation in the Pathogenesis of PD
The term “inflammation” defines a biological response by the immune system to an insult
that is physical, toxic or infective [34]. The CNS differs in its inflammatory response to the other
tissues. In general terms, cellular infiltration in the brain in response to inflammation is weak and
delayed; however, many inflammatory responses can be induced rapidly [35]. These include the
activation of microglia and the expression and release of classic inflammatory mediators, such as acute
phase proteins, eicosanoids, proteins of the complement and cytokines [36]. Chronic inflammation
is a contributing feature of many neurodegenerative diseases [37]. In fact, different markers have
been observed in the SNpc and STR of PD patients [38]. In 1988, McGeer and colleagues provided
the first link between inflammation and PD, showing an increase of human leucocyte antigen D
related (DR)-positive microglia in the substantia nigra (SN) of patients [39]. In recent years, it has
been demonstrated that there is an increase in proinflammatory mediators’ activation also in the
STR [40]. Although it has been studied for years, the inflammatory response related to PD has not
been clarified yet, especially from the molecular angle. It is now known that PD is characterized by
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the accumulation of microglia and astrocytes and T cell infiltration associated with modifications
in glial cell morphology and function. Considering the involvement of neuroinflammation in the
progression of PD, several studies showed the potential use of anti-inflammatory drugs to reduce the
risk of an individual developing PD [41,42]. Unfortunately, these studies have generated conflicting
data [43], and preclinical studies on neuroinflammatory processes have not been translated into clinical
practice yet.
3.1. Microglia as a Mediator of Neuroinflammation in PD
Different populations of macrophages are present in healthy brain tissue, each with a distinct
phenotype and morphology. The most abundant of these macrophages are microglia, the resident
immune cells of the brain parenchyma [44]. In the healthy brain, microglia are in a resting state
characterized by a ramified morphology that permits receiving signs of distress from the tissue
environment [45]. Following a brain insult, the tight junctions between endothelial cells become
permeable, allowing peripheral immune cells to infiltrate brain parenchyma [46]. At the same time,
immunogenic molecules are released, leading microglia to adopt an activated morphology and to
secrete proinflammatory factors, including interleukin (IL)-1β, tumor necrosis factor (TNF)-α and
ROS [45]. The normal activation protects neurons from injuries and maintains homeostasis in the brain.
After the resolution of the activation, microglia return to the resting state.
Although the link between microglia activation and dopaminergic neuron death in PD is still
under investigation, PD patients and animal models have shown that persistent microglia activation
causes deleterious effects, which lead to the loss of dopaminergic neurons [47,48].
One of the main damaging effects mediated by microglia is the activation of the nuclear factor-κB
(NFκB) pathway and the consequently increased release of proinflammatory cytokines, such as IL-1β
and TNF-α [49,50]. Among the cytotoxic mechanisms induced by proinflammatory cytokines in PD,
the activation of inducible nitric oxide synthase (iNOS) is the best clarified. iNOS produces high levels
of NO and superoxide radicals, which can directly or indirectly induce neuronal death in PD brain [51].
Thus, the study of the plasticity of microglia response, which could be deleterious or beneficial for
brain health, may be a useful tool to interfere with PD progression.
3.2. Astrocytes as Mediator of Neuroinflammation in PD
Astrocyte reaction is another well-documented neuropathological characteristic in the SNpc of
PD patients [43,44]. Astrocytes form the glia around blood vessels, limiting the entry of immune
cells into the CNS through BBB [52]. Interesting evidence showed the emerging role of astrocytes in
neuroinflammation associated with PD [53]. As shown by Wu et al. in 2002, the SNpc of postmortem
PD patients presented an increased number of astrocytes and glial fibrillary acidic protein (GFAP
immunoreactivity [54]. This study demonstrated that the amount of GFAP-positive astrocytes is
inversely proportional to the number of dead dopaminergic cells, so neurons are more susceptible
to the neurodegenerative process if there is a lack of astrocytes [55]. It has been also discussed
that the decreased integrity of astroglial cells, possibly related to the accumulation of nigral α-syn,
could actually contribute to the loss of nigral neurons [56]. Microglia and astrocytes are both
involved in the neuroinflammatory response, and usually, they are converted to the reactive isoform
in concert; for this reason, it is not easy to distinguish their contribution to neuroinflammation.
Astrocytes activation is considered as a response that although initially beneficial, is later corrupted
by disease alterations [57]. From the moment that neuronal damage can be activated or be prevented
by astrocytes, the imbalance between these actions could be crucial for the onset and progression of
PD [53,56]. The comprehension of the role of astrocytes in PD may be essential to improve therapies
and to develop new drugs for PD treatment.
Int. J. Mol. Sci. 2016, 17, 1454 5 of 18
3.3. T Cell Infiltration as a Mediator of Neuroinflammation in PD
The protection exerted by the BBB makes the brain an immune-privileged system. However,
the peripheral leukocyte migration and infiltration occur in PD, probably because both the animal
model and clinical syndrome exhibit BBB dysfunction. Different studies have demonstrated the
infiltration of immune cells in the brain, which consisted of a heterogeneous population of both CD8+
and CD4+ cells [58]. Compelling evidence suggested that this infiltration of peripheral lymphocytes
through BBB occurred because activated microglia in PD brains release proinflammatory cytokines
that act on the BBB and attract lymphocytes [59]. In addition, there are studies that indicate that
nitrated α-syn activated peripheral leukocytes, stimulating them to expand into different T cells,
and mediated adaptive immune responses in potentiating microglial activation and exacerbating
neuronal death [60]. Recently, Brochard et al. demonstrated that the removal of CD4+, but not of
CD8+ T cells, in mice greatly reduced 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced
nigrostriatal cell death. These studies highlighted that the adaptive immune system, like the innate
immune system, may actively participate in the pathogenesis of PD. However, more work needs to be
done to find out how they will be a potential target for PD therapy.
Taking into account the multifactorial nature of PD pathogenesis, positive effects from
anti-inflammatory drugs could only be possible if their administration were combined with compounds
targeting other deleterious pathways, such as anti-apoptotic or antioxidants, or it would be even more
exciting to find a pleiotropic compound that embodies all of these benefits.
4. Isothiocyanates and PD
A neuroprotective strategy proposes natural antioxidant molecules as an alternative form
of treatment for the prevention of neurological pathologies, such as PD [61]. In this context,
vegetables from the cruciferous family have generated interest as having potential neuroprotective
compounds. The Brassica family is the largest and most widely-consumed group of plants in Europe
and all over the world. This family includes around 340 genera and about 3700 species characterized
by different levels of nutrients [62]. The beneficial effects of Brassica vegetables on human health
have been linked to phytochemicals that prevent oxidative stress, induce enzymes of detoxification,
stimulate the immune system, decrease the risk of cancer and reduce the proliferation of cancer cells,
as well [63].
Brassica vegetables contain many valuable metabolites and are a considerable source of
antioxidants. The attention reserved for these vegetables is due to their unique constituents,
glucosinolates. They present three different components: a β-thioglucose part, a sulfonated oxime
and a variable aglycone side chain derived from α-amino acid [64]. Glucosinolates are not bioactive
compounds, and in normal conditions, they are hydrolyzed slightly. When plant tissue damage
occurs by disruption, glucosinolates are hydrolyzed quickly upon a β-thioglucoside glucohydrolase
enzyme, called myrosinase. This enzyme is located in myrosin cells, and the resulting product is
a highly unstable aglycone intermediate that leads to the production of thiocyanates, nitriles, goitrin,
epithionitriles and ITCs [65]. The spatial separation of myrosinases from glucosinolates is the basis
of the glucosinolate-myrosinase system that has been described as the plants’ protective factor from
insect and pathogen insults [66]. Given that myrosinases are sensitive to mild heating and cooking,
when humans consume cruciferous vegetables, the main source of myrosinase activity derives from
gut microflora [67]. ITCs are reactive electrophiles that are able to modify proteins that are crucial to
activate noxious responses, interfere with carcinogen metabolism, reduce tumor development and
modify the production of inflammatory cytokine [13,49]. Accumulating evidence has suggested that
their activities are expressed through signaling pathways involved in detoxification, inflammation,
apoptosis and cell cycle regulation by the induction of enzyme systems of phases I and II [68]. Indeed,
the central electrophilic carbon of ITCs (R–N=C=S) undergoes rapid addition reactions with biological
nucleophiles. Drobnica et al. demonstrated the ability of ITCs to react with thiol groups up to
one thousand times faster than with amino groups. This ability made proteins with cysteine residues
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particularly sensitive targets for modification by ITCs [69]. ITCs are initially conjugated to GSH
through catalysis by glutathione-S-transferase (GST). Once ITCs are conjugated, they are rapidly
effused from cells, and the acetylation that follows the removal of glutamate and glycine generates
a mercapturic acid (N-acetylcysteine isothiocyanate) residue excreted into urine. However, in all of
these compounds, the most important characteristic is that the cysteine-isothiocyanate conjugate is
able to dissociate back to the original ITCs [70]. This reversibility is fundamental to transport them
throughout the body and to enhance the reaction of free ITCs with more reactive targets [71]. In cells,
the protective responses to oxidative damage are essentially three: the cis-acting enhancer sequence
termed the antioxidant response element (ARE) that is included in genes, such as heme oxygenase-1
(HO-1), the transcription factor nuclear factor (erythroid-derived 2)-like 2 (NrF2) that is considered
as a guardian of the cellular redox homeostasis and the cytosolic NrF2-repressor protein, the Kelch
enoyl-CoA hydratase (ECH)-associated protein 1 (Keap1), characterized by the high content of cysteine
groups [11,71,72]. Under normal conditions, NrF2 is held by Keap1 in the cytoplasmatic fraction.
In the presence of an oxidative stimulus, NrF2 is released and translocated into the nucleus, where it
heterodimerizes with the small Maf proteins enhancing the binding to ARE genes in the promoter
regions. This event induces the NrF2/ARE pathway at the transcriptional level to restore homeostasis
through upregulation of phase II detoxification enzymes [11,68,72,73].
Several in vitro studies clearly indicated that the activation of NrF2 results in the protection
against hydrogen peroxide (H2O2)-induced oxidative stress [74]. As shown by Ramos-Gomez et al.,
the critical role of NrF2 is highlighted by its absence, in this case, the sensitivity to xenobiotics
spreads and oxidative stress is increased, leading to the amplification of cytokine production,
as NF-κB is more readily activated in oxidative environments [75,76]. Animal models of PD showed
a dramatic loss of dopaminergic neurons in transgenic animals with NrF2 knockout, while the
overproduction of this enzyme or the downregulation of Keap1 have neuroprotective effects on
them [77,78]. A similar increase in the sensitivity of the NrF2-deficient mice has been observed in
the 6-hydroxydopamine (6-OHDA) model both in vitro and in vivo; in particular, there was a more
significant neurodegeneration in the presence of NrF2 deficiency than in wild-type counterparts [79].
Similarly, also in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model, researchers
observed a more impactful loss of DA in the STR of NrF2 knockout mice than in the wild-type at
different MPTP doses [80,81]. It is well known that the NrF2 and NFκB pathways could interplay
through multiple molecular interaction, and their imbalance is associated with different diseases,
ranging from cancer, autoimmune disorders and neurodegeneration [82]. The modulation of NrF2
in response to NFκB activation could be a protective mechanism against the consequences of
inflammation [83]. There are several mechanisms by which p65 (the canonical NFκB subunit) can
exert a negative role in the regulation of NrF2 activity. For instance, Rushwort et al. [84] demonstrated
that NrF2 contains several κB sites in its promoter, which are regulated by p65. In addition,
p65 can induce the repression of transcription by deacetylation of histones, associating with histone
deacetylase [85]. Finally, Jiang et al. [86] showed in 2014 that the increase in Nrf2 activity prevents the
activation of p65, by accumulation of GSH [86]. However, despite the known evidence for functional
interactions between these two pathways, many aspects of the nature of their cross-talk require
further investigations.
The relevance of the NrF2/HO-1 axis in downregulation of brain inflammation and the design of
drugs that could pass through the BBB to modulate NrF2 activity are fundamental issues that need to
be solved [87]. ITCs are known not only to be potent NrF2 activators and to exhibit antioxidant effects
via the upregulation of ARE-driven genes, but also to decrease the inflammatory response through
the NFκB pathway [69]. In oxidative conditions, NFκB is activated, resulting in further expression of
pro-inflammatory cytokines [88]. Once NFκB is released, it is accumulated in the nucleus, where it
induces the transcription of target genes involved in cell inflammatory responses [89]. The suggested
neuroprotective mechanism of ITCs is summarized in Figure 1. Even if the interaction between
ITCs and Keap1 is still under investigation, it might be triggered by protein kinases or as a direct
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reaction of ITCs with the sulfhydryls groups of cysteine residues in Keap1, both mechanisms result in
conformational changes responsible for the release of NrF2 that can move to the nucleus [90].
ITCs and SFN in particular have demonstrated anti-inflammatory activity, as shown by Heiss et al.
in the RAW 264.7 macrophage cell line [12]. The authors showed that SFN was able to inhibit NFκB
release and the transactivation of κB-dependent genes. The capacity to downregulate the NFκB
pathway during inflammation was demonstrated also by Brandenburg et al. in a study aimed to
investigate the capacity of SFN to inhibit the signal transduction pathways involved in response to LPS
insult on primary rat microglia and on murine microglial cells, recombinant retrovirus (v-raf/v-mic)
transformed (BV2) [91].
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Figure 1. Summary of the main mechanis s involved in the neuroprotective activity of isothiocyanates
(ITCs). ITCs are known not only to be potent NrF2 activators and to exhibit antioxidant effects via the
upregulation of ARE-driven genes, but also to decrease the inflammatory response through the NFκB
pathway. Red arrows: blocked pathways; green arrows: enhanced pathways; black arrows: normal
pathway of NFκB.
4.1. Sulforaphane
SFN, one of the most studied ITCs, is a natural compound highly present in cruciferous vegetables,
like broccoli, cauliflower, Brussel sprouts and cabbage. Interestingly, it has shown protective effects
on neurons, decreasing both microglia activation and the upregulation of inflammatory markers
following the endotoxi s’ injection [87 92–94]. Jazwa et al. showed in an MPTP mouse model of
PD that the intraperitoneal (i.p.) injection of SFN led to an upregulation of pha e II antioxidant
enzymes (HO-1, NQO1) and to an increase of NrF2 proteins’ level in basal ganglia [95]. In addition,
the intrathecal (i.t.) administration of SFN reduced astrogliosis and the expression of cytokines
after spinal nerve transection; moreover, it counteracted the development of neuropathic pain [96].
The anti-inflammatory properties of SFN has been well-documented in studies conducted on NrF2−/−
macrophages treated with LPS, in which there was a consistent incr ase in pr inflammatory markers,
such as cyclooxygenase-2 (COX-2), iNOS, IL-6 and IL-8 [97,98]. At the same time, SFN was able
to reduce astrocytes and microglia activation, as shown by Jazwa et al. [95]. In our laboratory,
Tarozzi et al. demonstrated that the elevation of GSH in SH-SY5Y cells treated with 6-OHDA
after a pretreatment with SFN could be determinant to prevent the early redox status impairment
responsible for mitochondrial ysfunction and apoptosis [99]. We have also demonstrated that the i.p.
administration of SFN in a 6-OHDA murine model of PD was able to increase GSH and related
enzymes levels, as well as to modulate extracellular signal-regulated protein kinase 1/2 (ERK1/2)
activity [18]. Moreover, Deng et al. showed the capacity of SFN to counteract toxicity induced by
6-OHDA through the activation of the NrF2-ARE pathway [100,101]. Thus, the neuroprotective activity
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of SFN is associated with a mechanism involving nuclear translocation of NrF2 and the subsequent
increase of phase I and II detoxifying enzymes, with simultaneously activation of ERK 1/2 and Akt
pathways [102,103], and finally, with the ability to counteract neuroinflammation [104].
Therefore, due to the relation between NrF2/ARE pathway and SFN mechanism of action, we can
affirm that it could be an excellent candidate for the modulation of brain inflammation and oxidative
stress in neurodegenerative conditions, such as PD.
4.2. Erucin
Although much research has focused mainly on SFN, other ITCs, such as erucin (ER),
are promising. ER (4-(methylthio)butyl ITC) is a hydrolysis product of glucoerucin (GER), which is
found in arugula, and an in vivo reduction product of SFN. Clarke et al. showed the interconversion
of SFN into ER in the urine of individuals consuming fresh broccoli sprouts or supplements [105].
Although the biological effects of ER are still poorly investigated, this compound has shown promising
efficacy for anticancer in several studies [106,107]. Different mechanisms of chemoprevention, such as
the alteration of phase I, II and III enzymes, regulation of cell proliferation and downregulation
of androgen receptor signaling, can be exerted by ER [108]. In a recent study conducted by
Yehuda et al., also the anti-inflammatory effects of ER were investigated. The study reported the
ability of this ITC to decrease the transcription of proinflammatory molecules (TNF-α, IL-1β and
IL-12) in THP-1 human acute monocytic leukemia cells, treated with LPS [109]. In addition, Cho et
al. demonstrated in LPS-stimulated macrophages its potent anti-inflammatory properties mediated
through the inhibition of NFκB signaling. They also showed the ability of ER to inhibit inflammatory
responses efficiently in mouse skin at low doses. These results suggest the potential of this ITC as
an anti-inflammatory agent [110]. In addition, Wagner et al. showed the effect of myrosinase-treated
glucoerucin (GER), which releases ER, on HO-1 expression and NrF2 signaling in cultured cells
and in mice. They suggested that ER induced NrF2 via ERK1/2-, p38- and JNK-dependent signal
transduction pathways and HO-1 expression primarily through p38 signaling [111]. In our previous
study, we demonstrated that ER prevented the oxidative damage induced by 6-OHDA in SH-SY5Y
cell line. At the cytosolic level, ER increased both GSH and the antioxidant capacity. The increased
resistance to apoptotic neuronal death in SH-SY5Y cells has been linked to higher levels of GSH [112].
ER showed an interesting profile of antioxidant, anti-inflammatory and neuroprotective effects similar
to those observed with SFN. These findings suggested that the neuroprotective effects of SFN recorded
in various animal models could also be ascribed to its metabolic conversion to ER. Due to the lack of
data on animal models of neurodegeneration, further studies are warranted to investigate the potential
in vivo neuroprotective role of ER.
4.3. Phenethyl Isothiocyanate
Phenetyl isothiocyanate (PEITC) is an organosulfur bioactive compound that has been found
in cruciferous vegetable, especially in seeds of winter cress. PEITC is released from its glucosinolate
precursor gluconasturtiin (GNS) by enzymatic hydrolysis [113]. This ITC has attracted researchers’
attention because of its high potency against several tumors, such as those of the lung, breast, pancreas
and colon [114,115]. In addition, PEITC presents a low in vivo toxicity, as shown in animal models
treated with equivalent anticarcinogenic doses or at higher doses [116]. PEITC is characterized by a high
oral bioavailability and fast absorption probably due to the low molecular weight [114]. PEITC has
shown potent antioxidant and anti-inflammatory activities [117]. In addition, PEITC showed a low
clearance rate. After absorption, the molecule is rapidly metabolized mainly through the mercapturic
acid pathway [118]. PEITC reacts with GSH, forming the phenethyl isothiocyanate-glutathione
(PEITC-GSH) conjugate catalyzed by GST in the cytosol [119]. Several studies reported the ability of
PEITC to modulate inflammation by the suppression of the expression of iNOS, COX-2 and IL-1β
macrophages [117,120]. In 2013, Park et al. demonstrated that PEITC suppressed the target gene
expression, IP-10, induced by lipopolysaccharide (LPS) and the transcriptional activation of interferon
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regulatory factors 3 (IRF3) by inhibiting the interferon-β (TRIF)-dependent signaling pathway of
Toll-like receptors [121]. The anti-inflammatory action of this ITC is also related to the ability to interact
with the NrF2 pathway, as shown by Boyanapalli et al. [122]. They used a transgenic mouse knockout
model for NrF2 to isolate peritoneal macrophages that were pretreated, after isolation, with PEITC
and lesioned with LPS. The results obtained showed that the induction of NrF2 is essential to obtain
a response by PEITC treatment in inflammation countering [122].
4.4. 6-(Methylsulfinyl)hexyl Isothiocyanate
Wasabi (Wasabia japonica) is a member of the Brassicaceae family of vegetables, and its rhizome
is a very popular pungent spice in Japan. Wasabi differs from other Brassicaceae species because it
contains a higher concentration of long-chain ITCs. The major compound is the 6-(methylsulfinyl)hexyl
isothiocyanate (6-MSITC) that has shown the ability to inhibit proinflammatory and prooxidant
factors [17,123]. Several studies demonstrated that COX-2 and NO activations by LPS are efficiently
counteracted by 6-MSITC treatment in a murine macrophage cell line [124,125]. Chen et al. showed
that 6-MSITC modulated several genes associated with inflammatory responses, regulating also
cytokines expression [126]. In animal experiments, 6-MSITC is rapidly absorbed into the body and
induces hepatic phase II detoxification enzymes more potently than SFN [127]. In the same study,
the authors showed that 6-MSITC is a potential activator of the NrF2/ARE-dependent detoxification
pathway, by activating the antioxidant response element (ARE) and inducing nuclear localization of
NrF2. Moreover, Mizuno and colleagues investigated the effect of SFN and 6-MSITC on oxidative
stress-induced cytotoxicity using primary neuronal cultures of rat striatum [128]. They demonstrated
that 6-MSITC was more potent than SFN in inducing the expression of γ-glutamylcysteine synthetase
and HO-1. However, they could find no difference for the cytoprotective effect and for the modulation
of intracellular GSH between SFN and 6-MSITC. Results obtained in our laboratories highlighted that
the administration of 6-MSITC for one month exerted neuroprotective effects in the 6-OHDA model of
PD. Indeed, 6-MSITC treatment resulted in a significant decrease in oxidative stress and apoptotic cell
death, leading to an improvement of behavioral impairments [17]. These findings suggested that this
ITC may be a promising neuroprotective compound against neurodegeneration that occurs in PD.
4.5. Novel Compounds
Naturally-occurring ITCs are known to possess chemopreventive and neuroprotective properties.
Recent studies investigated the effects of synthetic ITCs in order to ameliorate SFN safety, in the case
that SFN cytotoxicity will become a concern in future therapeutic applications. Researchers tried
to optimize natural compound efficacy by substitution of the aromatic rings in place of the methyl
group on the SFN structure. A good example is the novel compound ITC-3 synthetized by Lee et al.
that led to the elevation of nuclear and total levels of the transcription factor NrF2 and interacted
with its binding protein Keap1 with high affinity. At the same time, ITC-3 was able to reduce the
production of the proinflammatory mediators significantly in LPS-activated BV-2 microglial cells [129].
Finally, in the same study, the authors showed its neuroprotective activity in the MPTP mouse model
of PD, by attenuating the loss of tyrosine hydroxylase-immunopositive nigrostriatal DAergic neurons,
suppressing microglial activation and abolishing PD-associated motor deficits.
Another interesting synthetic ITC is 4-iodophenyl isothiocyanate (4-IPITC). Wellejus et al. showed
its neuroprotective activity on primary cortical neurons exposed to various insults, such as excessive
glutamate exposure, oxygen-glucose deprivation, oxidative stress and 1-methyl-phenylpyridinium
(MPP+). Moreover, they studied the effects of 4-IPITC in a murine PD model. Although the number of
animals in this MPTP study was limited, 4-IPITC showed the potential to counteract neurotoxicity [130].
Taking into account these considerations, novel compounds that target both oxidative damage and
inflammatory response would be useful toward the development of a disease-modifying therapy
for PD.
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5. Conclusions
Neuroinflammation is, together with oxidative stress, one of the most preponderant contributors
to neurodegenerative diseases. The tight correlation between these factors is responsible of the vicious
cycle that is easily observed in the evolution of neurodegenerative diseases. In diseases such as PD,
where the multifactorial nature is now recognized, the importance to find out an efficient multitarget
therapy is determinant to counteract the diseases’ evolution. To date, no efficient therapy, able to
arrest or slow down PD, is available. In this view, ITCs have shown an interesting ability to modulate
oxidative stress and inflammatory processes (see Tables 1 and 2 for a summary). Due to the capacity
of these compounds to interact with the NrF2 pathway, new studies are projected to evaluate new
molecules synthetized from the ITCs’ structure to improve chemical characteristic, with the aim to find
drugs able to counteract the neurodegenerative processes’ evolution efficiently.








LPS 1 1 µg/mL SFN 2 5–40 µM [97]
SH-SY5Y cell 3
H2O2 4 300 µmol/L SFN 0.63–5 µmol/L [99]6-OHDA 5 100 µmol/L
PC12 6 cell line 6-OHDA 80 µM SFN 5 µM [100]
Primary cortical neurons 5-S-cysteinyl-dopamine 100 µM SFN 100 nM [102]
CATH.a cell 8
BH4 7 200 µM
SFN 0.5–5 µM [93]
6-OHDA 50 µM
MPP+ 9 2 mM













SH-SY5Y cell 6-OHDA 200 µmol/L ER 1.25–5 µmol/L [112]
Human plasma and urine Watercress 100 g [114]
RAW 264.7 LPS 1 µg/mL
PEITC 19
100 mM [117]MSO 20
RAW 264.7 LPS 500 ng/mL SFN 0.4–50 µM [12]
RAW 264.7 LPS 1 µg/mL Barbarea verna 1–20 µM [120]
HL60 cell line 21
PEITC
metabolites 0.1–100 µM [118]
RAW 264.7 LPS 110 ng/mL PEITC 20 µM [121]
Peritoneal macrophages
of C57BL/6 mice




from E18 Wistar rats
Glutamate 20 µM
4-IPITC 22 0.1–10 µM [130]H2O2 45 µM
Mesencephalon neurons MPP+ 4 µM
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RAW 264.7 LPS 40 ng/mL 6-MITC 23 16 µM [124]
RAW 264.7 LPS 40 ng/mL 6-MITC 8 µM [126]














BV-2 cells LPS 0.2 µg/mL 1–20 µM
Abbreviations: 1 Lipopolysaccharide; 2 sulforaphane; 3 neuroblastoma cell line; 4 hydrogen peroxide;
5 6-hydroxydopamine; 6 pheochromocytoma rat adrenal medulla derived cell line; 7 tetrahydrobiopterin;
8 catecholaminergic cell line; 9 1-methyl-4-phenylpyridinium; 10 α-methyl-p-tyrosine; 11 neuroblastoma
cell line; 12 mouse leukemic monocyte macrophage cell line; 13 erucin; 14 human Caucasian colon
adenocarcinoma grade II cell line; 15 glucoerucin; 16 glucoraphanin; 17 sinigrin; 18 gluconasturtiin; 19 phenethyl
isothiocyanate; 20 8-methylsulfinyloctyl; 21 human promyelocytic leukemia cells; 22 4-iodophenyl isothiocyanate;
23 6-(methylsulfinyl)hexyl isothiocyanate; 24 rat liver epithelial cell line.




Toxins Doses Molecules and Sources Doses
NrF2−/− mice MPTP 1 30 mg/kg SFN 2 50 mg/kg [95]
Nox2−/− mice







NrF2−/− mice Broccoli seeds 15% on weight [92]
C57BL/6 mice 6-OHDA 4 2 µL, 4 µg/mL SFN 5 mg/kg [18]
Sprague-Dawley rats OKA 5 200 ng SFN 5 mg/kg [104]







Wistar rats λ-Carrageenan 100 µL, 1% PEITC 12 oil 200 mg/kg [120]
Dark agouti rats Myelin oligodendrocyteglycoprotein 0.7 mg/mL 10–40 mg/kg [130]
C57BL/6 mice MPTP 20 mg/kg 5 mg/kg
C57BL/6 mice MPTP
40 mg/kg






C57BL/6 mice 6-OHDA 2 µL, 4 µg/mL 6-MITC 5 mg/kg [17]
C57BL/6 mice MPTP 20 mg/kg ITC-3 30 mg/kg [129]
Abbreviations: 1 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2 sulforaphane; 3 fractalkine receptor;
4 6-hydroxydopamine; 5 okadaic acid; 6 12-O-tetradecanoylphorbol-13-acetate; 7 erucin; 8 glucoerucin; 9 glucoraphanin;
10 sinigrin; 11 gluconasturtiin; 12 phenethyl isothiocyanate; 13 6-(methylsulfinyl)hexyl isothiocyanate.
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